Patrick Mismetti

TL;DR: For the treatment of acute venous thromboembolism, a fixed dose of dabigatran is as effective as warfarin, has a safety profile that is similar to that of warfar in, and does not require laboratory monitoring.

TL;DR: Among hospitalized patients with severe acute pulmonary embolism, the use of a retrievable inferior vena cava filter plus anticoagulation compared with anticogulation alone did not reduce the risk of symptomatic recurrent pulmonary emblism at 3 months, and these findings do not support theUse of this type of filter in patients who can be treated with antICOagulation.

TL;DR: An additional 18 months of treatment with warfarin reduced the composite outcome of recurrent venous thrombosis and major bleeding compared with placebo among patients with a first episode of unprovoked pulmonary embolism, but benefit was not maintained after discontinuation of anticoagulation therapy.

TL;DR: Anesthesiologists should be aware of the indications, potential complications and means of substitution of these agents and should not be withdrawn for most vascular procedures and in several additional settings.

TL;DR: LA and aCL were significantly associated with an increased risk of thrombosis, especially arterial, in patients without SLE, and the presence of low-quality studies may have led to overestimation of the magnitude of the associations.